Exploring a novel small molecule ERR agonist studied as a potential exercise mimetic compound.
SLU-PP-332 is a small molecule agonist of the estrogen-related receptors (ERRs), a family of nuclear receptors that play central roles in energy metabolism and mitochondrial function. Unlike traditional peptides, SLU-PP-332 is a synthetic small molecule compound developed at Saint Louis University — the abbreviation "SLU" in its name reflects this institutional origin. The compound was designed to activate all three ERR subtypes: ERRα, ERRβ, and ERRγ, each of which contributes to the regulation of metabolic gene networks throughout the body.
SLU-PP-332 has garnered significant attention in the research community as a candidate "exercise mimetic" — a compound capable of activating some of the same biological pathways that are normally triggered by physical exercise. This concept has broad implications for metabolic research, making SLU-PP-332 one of the most discussed compounds in recent exercise physiology and pharmacology literature.
The development of SLU-PP-332 stems from decades of research into the ERR family of orphan nuclear receptors. ERRα, ERRβ, and ERRγ were originally named for their structural similarity to estrogen receptors, though they do not bind estrogen and function through distinct ligand-independent and ligand-dependent mechanisms. These receptors are highly expressed in metabolically active tissues such as skeletal muscle, heart, and brown adipose tissue, where they regulate the expression of genes involved in oxidative phosphorylation, fatty acid oxidation, and mitochondrial biogenesis.
Published research from 2023 demonstrated that SLU-PP-332 administration in mouse models led to measurable increases in exercise capacity and endurance performance. Animals treated with the compound showed enhanced fatty acid oxidation and improvements in markers associated with aerobic fitness, even in the absence of an exercise training regimen. These findings positioned SLU-PP-332 as one of the first well-characterized pan-ERR agonists with demonstrated in vivo activity in exercise-related endpoints, drawing interest from researchers studying metabolic diseases, muscle physiology, and energy homeostasis.
SLU-PP-332 exerts its effects by binding to the ligand-binding domains of ERRα, ERRβ, and ERRγ, stabilizing these receptors in an active conformation. Once activated, the ERRs recruit coactivator proteins and bind to ERR response elements (ERREs) in the promoter regions of target genes. This transcriptional activation upregulates a broad network of genes responsible for mitochondrial function, oxidative metabolism, and energy substrate utilization.
In skeletal muscle, ERR activation by SLU-PP-332 promotes a shift toward oxidative fiber type gene expression, enhances mitochondrial density, and increases the capacity for fatty acid beta-oxidation. These molecular changes mirror many of the adaptations observed following endurance exercise training, which is why the compound has been described as an exercise mimetic. The pan-ERR agonism — targeting all three receptor subtypes simultaneously — is believed to produce a more comprehensive metabolic response than selective activation of any single ERR subtype alone.
SLU-PP-332 is currently utilized in several preclinical research domains. Metabolic researchers employ the compound to study how ERR activation influences whole-body energy expenditure, glucose homeostasis, and lipid metabolism in rodent models. Exercise physiologists use it to investigate the molecular pathways underlying endurance adaptations and to determine which exercise-induced changes can be pharmacologically replicated without physical activity.
Additional research applications include studies of mitochondrial biogenesis and function, investigations into muscle fiber type composition and plasticity, and research into the ERR signaling axis as a potential target for metabolic syndrome and obesity-related conditions. Because SLU-PP-332 is a relatively novel compound with published data emerging in 2023, it represents an active and expanding frontier in nuclear receptor pharmacology and exercise science research.
SLU-PP-332 is supplied as a 5mg lyophilized powder. As a small molecule compound rather than a peptide, its molecular weight is characteristic of synthetic organic molecules rather than amino acid chains. Each vial is sealed under controlled conditions to preserve compound integrity and is available at $35 per unit.
SLU-PP-332 should be stored at -20°C for long-term preservation. The compound must be protected from light and moisture at all times, as exposure to either can compromise stability and research utility. Unopened vials stored under recommended conditions maintain their integrity for extended periods. When preparing for use, allow the vial to equilibrate to room temperature before opening to prevent moisture condensation on the lyophilized powder. Handle with appropriate laboratory gloves and use sterile technique throughout reconstitution and aliquoting procedures.
This product is sold exclusively for laboratory and scientific research purposes. It is not intended for human or veterinary use, diagnostic purposes, or therapeutic applications. All research must comply with applicable laws and institutional guidelines. By purchasing, you confirm you are a qualified researcher. Please review our full legal disclaimer.